The effect of meldonium on the heart rate variability in the complex therapy of patients with chronic heart failure and chronic obstructive pulmonary disease

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Chronic heart failure (CHF) in combination with chronic obstructive pulmonary disease (COPD) – common diseases in the clinical practice of a general practitioner.

Purpose: to study the effect of meldonium in the complex therapy on heart rate variability in patients with CHF and COPD.

Material and method. 60 patients were included in a randomized study. The age of the patients was 45–70 years. All the studied patients had CHF II A stage, II–III FC (clinical recommendations of the RSC, SHFS, 2020) and COPD I–III degree of airflow limitation (GOLD 2021 classification) without exacerbation. The patients were divided into 2 groups: the patients of the 1st group (the main group, n=30) with CHF and COPD received meldonium at a dose of 1000 mg/day in addition to the basic therapy, the patients of the 2nd group (the control group, n=30), were treated only basic drugs for CHF and COPD. The patients were followed up for 12 weeks.

Results. After 12 weeks of therapy with the inclusion of meldonium as part of the complex therapy of CHF and COPD, a significant decrease in the incidence of hypersympathicotonia, a decrease in the tension of the regulatory systems of the autonomic nervous system (ANS) was found.

Conclusion. A significant beneficial effect of meldonium as part of complex therapy on the state of the ANS in patients with CHF and COPD was established.

Texto integral

Acesso é fechado

Sobre autores

Mikhail Statsenko

Volgograd State Medical University of the Ministry of Healthcare of Russia

Autor responsável pela correspondência
Email: mestatsenko@rambler.ru
ORCID ID: 0000-0002-3306-0312

MD, professor, vice-rector for scientific work, head of the Department of internal medicine

Rússia, Volgograd

Svetlana Turkina

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: turkina.vlg@gmail.com
ORCID ID: 0000-0002-8844-2465

MD, professor of the Department of internal medicine

Rússia, Volgograd

Yulia Lopushkova

Volgograd State Medical University of the Ministry of Healthcare of Russia

Email: yulija.89@bk.ru
ORCID ID: 0000-0003-2259-2564

assistant at the Department of internal medicine

Rússia, Volgograd

Bibliografia

  1. Malyavin A.G., Martynov A.I., Adasheva T.V. et al. National clinical guidelines. Diagnostics and treatment of patients with chronic obstructive pulmonary disease and chronic heart failure. Developed by the Committee of Experts (RSMSIM). 2018. URL: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2018/ХОБЛ%20и%20и%20%ХСН%20рекомендации%20проект.pdf (date of access – 01.05.2022) (In Russ.)].
  2. Mareev V.Yu., Fomin I.V., Ageev F.T. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya = Cardiology. 2018; 58(6S): 8–158 (In Russ.). http://dx.doi.org/10.18087/cardio.2475. EDN: XUAREL.
  3. Voichenko T.Yu., Gorbunov V.V., Govorin A.V. et. al. Indices features of cardiac rhythm variability in ischemic heart disease in conjunction with chronical obstructive lung disease. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk). 2008; 81(6): 40–43 (In Russ.). EDN: JWBSWR.
  4. Gazizyanova V.M., Bulashova O.V., Khazova E.V. et al. Heart rate variability in patients with heart failure Combined with chronic obstructive pulmonary disease. Prakticheskaya meditsina = Practical Medicine. 2018; (1): 15–20 (In Russ.). EDN: YUZISC.
  5. Statsenko M.E., Lopushkova Yu.E. Study of heart rate variability in patients with chronic heart failure and chronic obstructive pulmonary disease. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine. 2021; 11(4): 277–283 (In Russ.). http://dx.doi.org/10.20514/2226-6704-2021-11-4-277-283. EDN: DHXLDF.
  6. Florea V.G., Cohn J.N. The autonomic nervous system and heart failure. Circ Res. 2014; 114(11): 1815–26. http://dx.doi.org/10.1161/CIRCRESAHA.114.302589.
  7. Van Gestel A.J., Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2010; 2(4): 215–22. http://dx.doi.org/10.3978/j.issn.2072-1439.2010.02.04.5.
  8. Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: A literature update. Int Arch Med. 2014; 7: 43. http://dx.doi.org/10.1186/1755-7682-7-43.
  9. Dzyurich T.A., Chesnikova A.I., Terentyev V.P. et al. Evaluation of diagnostic criteria of heart failure in patients with atrial fibrillation and chronic obstructive pulmonary disease. Kardiologiya = Cardiology. 2019; 59(S10): 4–12 (In Russ.). http://dx.doi.org/10.18087/cardio.n741. EDN: DGVHNC.
  10. Budnevsky A.V., Malysh E. Yu. Chronic obstructive lung disease as risk factor for cardiovascular disorders. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2016; 15(3): 69–73 (In Russ.). http://dx.doi.org/10.15829/1728-8800-2016-3-69-73. EDN: WCGFEF.
  11. Van Bilsen M., Patel H.C., Bauersachs J. et al.; Committee of the Heart Failure Association of the European Society of Cardiology. The autonomic nervous system as a therapeutic target in heart failure: A scientific position statement from the translational research. Eur J Heart Fail. 2017; 19(11): 1361–78. https://dx.doi.org/10.1002/ejhf.921.
  12. Spiesshoefer J., Regmi B., Ottaviani M.M. et al. Sympathetic and vagal nerve activity in COPD: Pathophysiology, presumed determinants and underappreciated therapeutic potential. Front Physiol. 2022; 13: 919422. https://dx.doi.org/10.3389/fphys.2022.919422.
  13. Nedogoda S.V. Meldonium as a supernosological drug. Consilium Medicum. 2020; 22(5): 57–61 (In Russ.). https://dx.doi.org/10.26442/20751753.2020.5.200208. EDN: LELZPK.
  14. Dzerve V.Ya., Kalvinsh I. Ya. Mildronat in cardiology. Research review. Riga: JSC Grindeks. 2013 (In Russ.).
  15. Grigoryan S.V., Hazarapetyan L.G., Stepanyan A.A. An experience of meldonium use in patients with ventricular arrhythmias of ischemic genesis. Kardiologiya = Cardiology. 2019; 59(7): 26–30 (In Russ.). https://dx.doi.org/10.18087/cardio.2019.7.n552. EDN: IUQFYT.
  16. Mikhin V.P., Khlebodarov F.E. Mildronate potential in patients with cardiovascular disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2010; 15(4): 83–92 (In Russ.). EDN: MUENKZ.
  17. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. New data on well-known drug: Focus on meldonium. Meditsinskiy sovet = Medical Council. 2021; (14): 110–117 (In Russ.). https://dx.doi.org/10.21518/2079-701X-2021-14-110-117. EDN: BWMPJE.
  18. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. et. al. New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2022; 16(6): 13–22 (In Russ.). https://dx.doi.org/10.21518/2079-701X-2022-16-6-13-22. EDN: PSWLDB.
  19. Turkina S.V., Statsenko M.E. Metabolic cardiac protection with Melidoni under ischemic heart disease: results and prospects. Lechashchiy vrach = Attending Physician. 2012; (7): 62–65 (In Russ.). EDN: SFPLOV.
  20. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. Possibilities of drug correction of the state of the main arteries and microcirculation in patients with chronic heart failure and chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2022; 16(17): 70–78 (In Russ.). https://dx.doi.org/10.21518/2079-701X-2022-16-17-70-78. EDN: EAQVTD.
  21. Rekhviashvili A., Kandashvili T., Giorgobiani T. Effect of mildronate on the existence and severity of fatigue in patients with heart failure. Sch J App Med Sci. 2021; 9(5): 723–30. https://dx.doi.org/10.36347/sjams.2021.v09i05.019.
  22. Belikova J., Lizogub V., Kuzminets A., Lavrenchuk I. Normalization of heart rate variability with taurine and meldonium complex in post-infarction patients with type 2 diabetes mellitus. J Med Life. 2019; 12(3): 290–95. https://dx.doi.org/10.25122/jml-2019-0052.
  23. Lippi G., Mattiuzzi C. Misuse of the metabolic modulator meldonium in sports. J Sport Health Sci. 2017; 6(1): 49–51. https://dx.doi.org/10.1016/j.jshs.2016.06.008.
  24. Statsenko M.E., Shilina N.N., Turkina S.V. The use of meldonium in the complex treatment of patients with heart failure in the early post-infarction period. Terapevticheskiy arkhiv = Therapeutic Archive. 2014; 86(4): 30–35 (In Russ.). EDN: SVPGGD.
  25. Berezutsky V.I. Potentials of meldonium in correction of autonomic imbalance. Farmateka. 2016; (18): 16–22 (In Russ.). EDN: XCIPAL.
  26. Statsenko M.E., Turkina S.V., Shalaeva S.S., Fabritskaya S.V. New potential of pharmaceutical correction of cardiac autonomic neuropathy in patients with type 2 diabetes mellitus and chronic heart failure. Russian Journal of Cardiology. 2011; 16(5): 40–46 (In Russ.). EDN: OIRUBJ.
  27. Kuznetsov A.A. Biophysics of the heart. A textbook in two books. Book 2. Electrocardiographic Holter monitoring for the study of heart rate variability in conditionally healthy people. Vladimir: Vladimir State University Press. 2013; 84 pp. (In Russ.). ISBN: 978-5-9984-0336-1.
  28. Babunts I.V., Mirijanyan E.M., Mashayeh Yu.A. Alphabet of heart rate variability analysis. Stavropol: Print Master. 2002; 1–112 pp. (In Russ.).
  29. Baevsky R.M., Ivanov G.G., Chireikin L.V. et al. Analysis of heart rate variability using various electrocardiographic systems. Vestnik aritmologii = Herald of Arrhythmology. 2002; (24): 65–86 (In Russ.) EDN: HSPLXF.
  30. Khodyrev G.N. Khlybova S.V., Tsikin V.I. et al. Methodological aspects of the analysis of temporal and spectral indicators of heart rate variability (literature review). Vyatskiy meditsinskiy vestnik = Vyatka Medical Bulletin. 2011; 3–4: 60–70 (In Russ.). EDN: TKOTLB.
  31. Akramova E.G. The features of time characteristics of heart rate variability in chronic obstructive pulmonary disease. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal. 2012; 93(2): 172–177 (In Russ.) https://dx.doi.org/10.17816/KMJ2281. EDN: OWJEDH
  32. Yudaeva Yu.A., Ivanov K.M., Kornyakova A.R. Heart rate variability in patients with a combined course of coronary heart disease and chronic obstructive pulmonary disease. Meditsinskiye nauki. Klinicheskaya meditsina = Medical sciences. Clinical medicine. 2011; 19(3): 123–131 (In Russ.)
  33. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. Possibilities of drug correction of the state of the main arteries and microcirculation in patients with chronic heart failure and chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2022; 16(17): 70–78 (In Russ.). https://dx.doi.org/10.21518/2079-701X-2022-16-17-70-78. EDN: EAQVTD.
  34. Statsenko M.E., Lopushkova Yu.Е., Derevyanchenko M.V. et. al. The effect of meldonium on arterial stiffness and the level of C-reactive protein in complex therapy of chronic heart failure and chronic obstructive pulmonary disease. Terapiya = Therapy. 2020; 6(5): 94–101 (In Russ.). https://dx.doi.org/10.18565/therapy.2020.5.94-101. EDN: EFGEFI.
  35. Eliseeva T.I., Balabolkin I.I., Oshevensky L.V. et al. Vegetative regulation and heart rate variability in children with bronchial asthma. Diagnostic and prognostic aspects. Monograph. 2009 (In Russ.).
  36. Statsenko M.E., Turkina S.V., Lopushkova Yu. E., Shilina N.N. The effects of meldonium baseline therapy on microcirculatory parameters and respiratory function in patients with chronic heart failure and chronic obstructive pulmonary disease. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Bulletin of the Volgograd State Medical University. 2015; (1): 74–78 (In Russ.). EDN: TNPXKT.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2023